Nathan Rice

Stock Analyst at Piper Sandler

(3.10)
# 1,172
Out of 5,127 analysts
61
Total ratings
52.63%
Success rate
11.6%
Average return

Stocks Rated by Nathan Rice

Bank First
Jan 26, 2026
Maintains: Neutral
Price Target: $142$150
Current: $151.62
Upside: -1.07%
First Mid Bancshares
Nov 3, 2025
Maintains: Overweight
Price Target: $49$48
Current: $44.13
Upside: +8.77%
Merchants Bancorp
Oct 30, 2025
Maintains: Overweight
Price Target: $41$42
Current: $45.06
Upside: -6.79%
Byline Bancorp
Oct 28, 2025
Maintains: Overweight
Price Target: $34$35
Current: $33.52
Upside: +4.42%
CVS Health
May 2, 2024
Maintains: Buy
Price Target: $85$74
Current: $75.77
Upside: -2.34%
Nicolet Bankshares
Jan 10, 2024
Assumes: Neutral
Price Target: $84
Current: $153.32
Upside: -45.21%
Align Technology
Dec 11, 2023
Downgrades: Sell
Price Target: $197
Current: $192.50
Upside: +2.34%
Elanco Animal Health
Apr 25, 2023
Maintains: Sell
Price Target: $11$9
Current: $24.83
Upside: -63.75%
IDEXX Laboratories
Jul 21, 2022
Upgrades: Buy
Price Target: $530$435
Current: $639.79
Upside: -32.01%
The Cigna Group
Dec 14, 2021
Initiates: Neutral
Price Target: $233
Current: $294.40
Upside: -20.86%
Initiates: Neutral
Price Target: $83
Current: $38.04
Upside: +118.19%
Initiates: Overweight
Price Target: $15
Current: $21.11
Upside: -28.94%